Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review

Dermatologic Therapy
Sohrab SalimiMohamad Goldust

Abstract

Psoriasis, a T-cell mediated chronic dermatosis, has a complex etiopathogenesis. There has been extensive research into the aberrant immune response, which leads to the formation of clinical lesions, and the need for developing better and safer drugs has been unrelenting. The past two decades of research has opened up new areas of the immune pathway that can be targeted in order to control the disease. Therefore, we have seen the emergence of biologics which either target T-cell receptors or inhibit Tumor Necrosis Factor-alpha (TNF-α) or inhibit interleukins (IL) like IL-12, IL-17, IL-17 receptor, and more recently IL-23. Drugs specifically targeting the p19 subunit of IL-23 have shown promising results in the management of chronic plaque psoriasis. This has given way to the development of a new class of biologics, that is, the IL-23p19 inhibitors that have a better safety profile as compared to its predecessors. In this review, we shall scrutinize the role of IL-23 and Th17 cell signaling in the evolution of the psoriatic lesions and summarize the clinical experience with IL-23p19 inhibitors especially mirikizumab in the treatment of chronic plaque psoriasis.

References

Jan 8, 2008·Current Rheumatology Reports·Erin FitchAndrew Blauvelt
Feb 15, 2008·The Journal of Dermatological Treatment·Alice B GottliebFrank Dann
Oct 16, 2010·F1000 Biology Reports·Paola Di Meglio, Frank O Nestle
May 19, 2011·Annals of Medicine·Emilie DuvalletMarie-Christophe Boissier
Aug 30, 2013·Indian Journal of Dermatology, Venereology and Leprology·Sanjeev J Aurangabadkar
Jan 1, 2014·Journal of the American Academy of Dermatology·Adriane A Levin, Alice B Gottlieb
Feb 1, 2014·Inflammatory Bowel Diseases·Ahmet EkenMohamed Oukka
Feb 7, 2014·Pakistan Journal of Biological Sciences : PJBS·H H QadimM Goldust
Feb 13, 2015·Anais Brasileiros De Dermatologia·Maria de Fátima Santos Paim de OliveiraGleison Vieira Duarte
Jul 15, 2015·The New England Journal of Medicine·Kenneth B GordonKristian Reich
Jun 1, 2015·Rheumatology and Therapy·Laura J SavagePhilip S Helliwell
Apr 20, 2017·The New England Journal of Medicine·Kim A PappSteven J Padula
May 13, 2018·Drugs·Anthony Markham
May 26, 2018·Therapeutic Advances in Chronic Disease·Tom C ChanJames G Krueger
Jul 24, 2018·Expert Opinion on Biological Therapy·Vito Di Lernia, Mohamad Goldust
Nov 24, 2018·American Journal of Clinical Dermatology·Zaina T Al-Salama, Lesley J Scott
Dec 7, 2018·Drug Design, Development and Therapy·Isabel M HaughAlan M Menter
Dec 24, 2018·The Journal of Allergy and Clinical Immunology·Sudha VisvanathanJames G Krueger
Mar 29, 2019·Expert Review of Clinical Immunology·Lluís Puig
Mar 30, 2019·American Journal of Clinical Dermatology·James E Frampton
Aug 30, 2019·Reumatologia·Katarzyna Banaszczyk
May 21, 2020·Dermatologic Therapy·Jianzhou YeXuesong Yang
May 23, 2020·Dermatologic Therapy·Jiajing LuYuling Shi

❮ Previous
Next ❯

Citations

Jul 10, 2021·Biologics : Targets & Therapy·Francesco BellinatoGiampiero Girolomoni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Related Papers

Psoriasis : Targets and Therapy
Christina FotiadouDemetrios Ioannides
JAMA : the Journal of the American Medical Association
April W Armstrong, Charlotte Read
© 2022 Meta ULC. All rights reserved